{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:28:26Z","timestamp":1791077306258,"version":"4.1.0"},"reference-count":146,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.lpm.2011.11.013","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T13:28:26Z","timestamp":1327930106000},"page":"e115-e135","source":"Crossref","is-referenced-by-count":83,"special_numbering":"P2","title":["Management of hemolytic uremic syndrome"],"prefix":"10.1016","volume":"41","author":[{"given":"Chantal","family":"Loirat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Saland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bitzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2011.11.013_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/sj.ki.5001581","article-title":"A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders","volume":"70","author":"Besbas","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.11.013_bib0010","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1055\/s-0030-1262881","article-title":"Treatment of typical (enteropathic) hemolytic uremic syndrome","volume":"36","author":"Bitzan","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.lpm.2011.11.013_bib0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00467-008-1087-4","article-title":"Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial","volume":"24","author":"Pape","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0020","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00467-010-1530-1","article-title":"Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome","volume":"25","author":"Weil","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(83)91795-6","article-title":"Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools","volume":"1","author":"Karmali","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0030","first-page":"1073","article-title":"Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome","volume":"365","author":"Tarr","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijmm.2005.06.009","article-title":"Enterohaemorrhagic Escherichia coli in human medicine","volume":"295","author":"Karch","year":"2005","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/521364","article-title":"Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum","volume":"196","author":"Wang","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0045","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic Profile of Shiga-Toxin-Producing Escherichia coli O104:H4 Outbreak in Germany - Preliminary Report","volume":"365","author":"Frank","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1258\/td.2007.070095","article-title":"Haemolytic uraemic syndrome in children admitted to a rural district hospital in Kenya","volume":"38","author":"Olotu","year":"2008","journal-title":"Trop Doct"},{"key":"10.1016\/j.lpm.2011.11.013_bib0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1681\/ASN.V124767","article-title":"Verocytotoxin-induced apoptosis of human microvascular endothelial cells","volume":"12","author":"Pijpers","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrmicro2279","article-title":"Shiga toxins\u2013from cell biology to biomedical applications","volume":"8","author":"Johannes","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/fmb.10.4","article-title":"Induction of apoptosis by Shiga toxins","volume":"5","author":"Tesh","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0070","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.V89.7.2429","article-title":"Apoptotic vascular endothelial cells become procoagulant","volume":"89","author":"Bombeli","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0075","doi-asserted-by":"crossref","first-page":"e6990","DOI":"10.1371\/journal.pone.0006990","article-title":"Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome","volume":"4","author":"Stahl","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2011.11.013_bib0080","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1128\/IAI.00383-10","article-title":"Shiga toxin 2 and flagellin from shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation","volume":"78","author":"Jandhyala","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.lpm.2011.11.013_bib0085","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00467-010-1522-1","article-title":"Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction","volume":"25","author":"Zoja","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0095","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/jama.290.10.1337","article-title":"Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial","volume":"290","author":"Trachtman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2011.11.013_bib0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mop.0000152997.66070.e9","article-title":"Hemolytic uremic syndrome; pathogenesis, treatment, and outcome","volume":"17","author":"Siegler","year":"2005","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0105","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1542\/peds.2005-0785","article-title":"Predictors of fatality in postdiarrheal hemolytic uremic syndrome","volume":"117","author":"Oakes","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.lpm.2011.11.013_bib0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/INF.0b013e31816a062f","article-title":"Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996\u20132006","volume":"27","author":"Espi\u00e9","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lpm.2011.11.013_bib0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/322598","article-title":"The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients","volume":"33","author":"Dundas","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ki.2010.174","article-title":"Chronic renal disease is more prevalent in patients with hemolytic uremic syndrome who had a positive history of diarrhea","volume":"78","author":"Sharma","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.11.013_bib0125","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.lpm.2011.11.013_bib0130","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(99)01251-9","article-title":"Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak","volume":"354","author":"Dundas","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0135","first-page":"585","article-title":"Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome","volume":"10","author":"Nakatani","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(73)80490-1","article-title":"Heparin therapy in the hemolytic-uremic syndrome","volume":"83","author":"Vitacco","year":"1973","journal-title":"J Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0145","first-page":"15","article-title":"Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial","volume":"41","author":"Loirat","year":"1984","journal-title":"Arch Fr Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s004670050413","article-title":"Steroids in the hemolytic uremic syndrome","volume":"12","author":"Perez","year":"1998","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0155","first-page":"22","article-title":"Decreased necessity for dialysis with loop diuretic therapy in hemolytic uremic syndrome","volume":"34","author":"Rousseau","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0160","first-page":"251","article-title":"Diuretics in acute kidney injury","volume":"75","author":"Karajala","year":"2009","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0165","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/171.4.1042","article-title":"A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome","volume":"171","author":"Armstrong","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0170","doi-asserted-by":"crossref","first-page":"e10167","DOI":"10.1371\/journal.pone.0010167","article-title":"Increased adherence and expression of virulence genes in a lineage of Escherichia coli O157:H7 commonly associated with human infections","volume":"5","author":"Abu-Ali","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2011.11.013_bib0175","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1086\/323082","article-title":"Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli","volume":"184","author":"Yamagami","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0180","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1128\/IAI.00592-08","article-title":"Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody","volume":"76","author":"Sauter","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.lpm.2011.11.013_bib0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00343-09","article-title":"Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody against shiga-like toxin 2 in healthy adults and pediatric STEC-infected patients","volume":"54","author":"L\u00f3pez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lpm.2011.11.013_bib0190","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1128\/AAC.49.5.1808-1812.2005","article-title":"Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers","volume":"49","author":"Dowling","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lpm.2011.11.013_bib0195","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1128\/AAC.01661-08","article-title":"Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers","volume":"53","author":"Bitzan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lpm.2011.11.013_bib0200","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0205","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0735","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Complement blockade in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0215","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"Stahl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by shiga toxin promotes exuberant c3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0225","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpeds.2007.03.055","article-title":"Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience","volume":"151","author":"Waters","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0235","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0240","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1542\/peds.2007-2017","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome: classification and the emergence of serotype 19A","volume":"125","author":"Copelovitch","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.lpm.2011.11.013_bib0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s004670100564","article-title":"Prognosis of Streptococcus pneumoniae-induced hemolytic uremic syndrome","volume":"16","author":"Nathanson","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0250","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1542\/peds.110.2.371","article-title":"Invasive pneumococcal disease and hemolytic uremic syndrome","volume":"110","author":"Brandt","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.lpm.2011.11.013_bib0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1440-1754.2009.01603.x","article-title":"Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children","volume":"45","author":"Prestidge","year":"2009","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.lpm.2011.11.013_bib0260","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00467-010-1687-7","article-title":"Hemolytic uremic syndrome associated with novel influenza A H1N1 infection","volume":"26","author":"Golubovic","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0265","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(79)91343-6","article-title":"Exchange transfusion with heparinised fresh blood in necrotising enterocolitis","volume":"1","author":"Poschmann","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0270","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2257.1985.tb00022.x","article-title":"Uncomplicated administration of blood products warmed to 37 degrees C in a patient with T activation of the red cell membrane","volume":"7","author":"Davis","year":"1985","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0275","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1537-2995.2000.40070801.x","article-title":"RBC T activation and hemolysis: implications for pediatric transfusion management","volume":"40","author":"Crookston","year":"2000","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2011.11.013_bib0280","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.inf.0000223494.83542.ad","article-title":"T-antigen activation for prediction of pneumococcus-induced hemolytic uremic syndrome and hemolytic anemia","volume":"25","author":"Huang","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lpm.2011.11.013_bib0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpeds.2007.04.057","article-title":"Hemolytic uremic syndrome and Streptococcus pneumoniae: improving our understanding","volume":"151","author":"Geary","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0290","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/j.1537-2995.2008.01871.x","article-title":"A severe case of atypical hemolytic uremic syndrome associated with pneumococcal infection and T activation treated successfully with plasma exchange","volume":"48","author":"Hopkins","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2011.11.013_bib0295","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-007-0604-1","article-title":"Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder","volume":"22","author":"Sharma","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0300","series-title":"GeneReviews [Internet]","article-title":"Disorders of Intracellular Cobalamin Metabolism","author":"Adams","year":"1993"},{"key":"10.1016\/j.lpm.2011.11.013_bib0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajmg.10499","article-title":"Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy","volume":"111","author":"Van Hove","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0310","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.ajkd.2004.12.004","article-title":"Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation","volume":"45","author":"Guigonis","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0315","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0320","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-1809.2009.00554.x","article-title":"Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome","volume":"74","author":"Sullivan","year":"2010","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0330","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/ndt\/gfq010","article-title":"Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)","volume":"25","author":"Westra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0335","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of Complement Factor H-Related CFHR1 Gene deletion is restricted to specific subgroups of patients with atypical Haemolytic Uraemic Syndrome","volume":"46","author":"Dragon-Durey","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0345","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ki.2009.472","article-title":"Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome","volume":"77","author":"Bienaim\u00e9","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2011.11.013_bib0350","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.lpm.2011.11.013_bib0355","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0360","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2011.11.013_bib0365","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome","volume":"114","author":"Roumenina","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0370","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0375","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0380","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0390","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0395","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0400","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0405","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.lpm.2011.11.013_bib0410","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1067\/mpd.2001.112649","article-title":"Familial hemolytic uremic syndrome associated with complement factor H deficiency","volume":"138","author":"Landau","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.lpm.2011.11.013_bib0415","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0420","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-008-0833-y","article-title":"Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation","volume":"23","author":"Davin","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0425","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00467-008-0803-4","article-title":"Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations","volume":"8","author":"Lapeyraque","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0430","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00467-006-0237-9","article-title":"Secondary failure of plasma therapy in factor H deficiency","volume":"21","author":"Nathanson","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0435","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00467-009-1306-7","article-title":"Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options","volume":"25","author":"De","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0440","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","article-title":"Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome","volume":"23","author":"Kwon","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0445","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ndtplus\/sfp109","article-title":"A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab","volume":"2","author":"Lionet","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.lpm.2011.11.013_bib0450","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2009.12.026","article-title":"Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies","volume":"55","author":"Boyer","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0455","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0460","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","article-title":"Complications of apheresis in children","volume":"47","author":"Michon","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.lpm.2011.11.013_bib0465","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.transci.2008.09.001","article-title":"World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry","volume":"39","author":"Witt","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.lpm.2011.11.013_bib0470","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneph.2010.98","article-title":"Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches","volume":"6","author":"Rosales","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0475","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00467-010-1556-4","article-title":"aHUS caused by complement dysregulation: new therapies on the horizon","volume":"26","author":"Waters","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010050451","article-title":"The development of atypical haemolytic uremic syndrome depends on complement C5","volume":"22","author":"Goicoechea de Jorge","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0485","series-title":"Targeting Complement C5 in atypical hemolytic uremic syndrome","author":"Salant","year":"2011"},{"key":"10.1016\/j.lpm.2011.11.013_bib0490","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.blre.2007.10.002","article-title":"Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria","volume":"22","author":"Brodsky","year":"2008","journal-title":"Blood Rev"},{"issue":"25","key":"10.1016\/j.lpm.2011.11.013_bib0495","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2011.11.013_bib0500","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2011.08690.x","article-title":"Management of paroxysmal nocturnal haemoglobinuria: a personal view","volume":"153","author":"Luzzatto","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0505","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0510","unstructured":"Fremont OT, Gordon CA, Hand MM. Eculizumab treatment for aHUS in a child with positive family history. PUB715, 42nd Annual Meeting of the American Society of Nephrology, San Diego, California, USA, Oct 27\u2013Nov\u00a01, 2009."},{"key":"10.1016\/j.lpm.2011.11.013_bib0515","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0520","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.lpm.2011.11.013_bib0525","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00467-010-1719-3","article-title":"Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome","volume":"26","author":"Lapeyraque","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0530","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ajh.21862","article-title":"Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome","volume":"5","author":"Prescott","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0535","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/CPAA.S17904","article-title":"Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical haemolytic uremic syndrome","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol Advance Appl"},{"key":"10.1016\/j.lpm.2011.11.013_bib0540","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0545","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","article-title":"Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome","volume":"9","author":"Chatelet","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0550","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.transproceed.2010.09.125","article-title":"Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report","volume":"42","author":"Ch\u00e2telet","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.lpm.2011.11.013_bib0555","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","article-title":"Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation","volume":"55","author":"Davin","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0560","doi-asserted-by":"crossref","unstructured":"Legault DJ, Boelkins MR. Successful treatment of aHUS recurrence and arrest of plasma exchange resistant TMA post-renal transplantation with the terminal complement inhibitor eculizumab. Poster 2421, 51st Meeting of the American Society of Hematology, New Orleans, LA, USA, Dec\u00a05\u20138, 2009.","DOI":"10.1182\/blood.V114.22.2421.2421"},{"key":"10.1016\/j.lpm.2011.11.013_bib0565","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","author":"Larrea","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.lpm.2011.11.013_bib0570","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","article-title":"Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation","volume":"26","author":"Al-Akash","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0575","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0580","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lpm.2011.11.013_bib0585","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0590","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2215\/CJN.10181110","article-title":"Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome","volume":"6","author":"Nester","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0595","unstructured":"Legendre C, Babu S, Furman RR, Sheerin NS, Cohen DJ, Gaber AO, et al. Safety and efficacy of Eculizumab in aHUS resistant to plasma Therapy: interim analysis from a Phase II trial. FC 406, 43rd Annual Meeting of the American Society of Nephrology, Denver, CO, USA, Nov 16\u201321, 2010."},{"key":"10.1016\/j.lpm.2011.11.013_bib0600","unstructured":"Muus P, Legendre C, Douglas K, Hourmant M, Delmas Y, Herthelius BM, et al. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: Interim analysis of a phase II trial. Poster 1274, 43rd Annual Meeting of the American Society of Nephrology, Denver, CO, USA, Nov 16\u201321, 2010."},{"key":"10.1016\/j.lpm.2011.11.013_bib0605","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.lpm.2011.11.013_bib0610","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0615","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02918254","article-title":"Complement biosynthesis by mononuclear phagocytes","volume":"12","author":"McPhaden","year":"1993","journal-title":"Immunol Res"},{"key":"10.1016\/j.lpm.2011.11.013_bib0620","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/db09-0700","article-title":"Complement factor H is expressed in adipose tissue in association with insulin resistance","volume":"59","author":"Moreno-Navarrete","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.lpm.2011.11.013_bib0625","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2249.1994.tb06033.x","article-title":"Regulation of C3 and factor H synthesis of human glomerular mesangial cells by IL-1 and interferon-gamma","volume":"95","author":"van den Dobbelsteen","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0630","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0161-5890(96)84610-4","article-title":"Interleukin-1 alpha enhances the biosynthesis of complement C3 and factor B by human kidney proximal tubular epithelial cells in vitro","volume":"33","author":"Gerritsma","year":"1996","journal-title":"Mol Immunol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0635","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2559.2009.03466.x","article-title":"Microchimerism in renal allografts: clinicopathological associations according to the type of chimeric cells","volume":"56","author":"Ferlicot","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.lpm.2011.11.013_bib0640","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1600-6143.2007.01888.x","article-title":"Recurrence of HUS due to CD46\/MCP mutation after renal transplantation: a role for endothelial microchimerism","volume":"7","author":"Fremeaux-Bacchi","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0645","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical Hemolytic-Uremic Syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2011.11.013_bib0650","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1600-6143.2009.02586.x","article-title":"Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome","volume":"9","author":"Le Quintrec","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0655","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0660","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1093\/ndt\/gfp377","article-title":"Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?","volume":"24","author":"Hirt-Minkowski","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0665","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.transproceed.2010.03.048","article-title":"A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report","volume":"42","author":"Albertazzi","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.lpm.2011.11.013_bib0670","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/S0140-6736(02)08560-4","article-title":"Combined kidney and liver transplantation for familial haemolytic uraemic syndrome","volume":"359","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2011.11.013_bib0675","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1600-6143.2005.00783.x","article-title":"Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation","volume":"5","author":"Remuzzi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0680","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00467-003-1371-2","article-title":"Attempted treatment of factor H deficiency by liver transplantation","volume":"19","author":"Cheong","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0685","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1600-6143.2006.01375.x","article-title":"Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation","volume":"6","author":"Saland","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0690","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-6143.2007.02029.x","article-title":"Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H","volume":"8","author":"Jalanko","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lpm.2011.11.013_bib0695","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2215\/CJN.02170508","article-title":"Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome","volume":"4","author":"Saland","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0700","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/j.1600-6143.2010.03228.x","article-title":"Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H","volume":"10","author":"Haller","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1016\/j.lpm.2011.11.013_bib0705","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2010.08295.x","article-title":"Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome","volume":"150","author":"S\u00e1nchez-Corral","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2011.11.013_bib0710","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.ajkd.2011.04.008","article-title":"Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor h","volume":"58","author":"Wilson","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.lpm.2011.11.013_bib0715","unstructured":"Source: \u201c1 Month, 3 Month, 1 Year, and 5 Year Patient Survival for Kidney-Liver Transplants from 2001 to 2005\u201d analyses prepared by the Scientific Registry of Transplant Recipients (SRTR), under contract with the U.S. Department of Health and Human Services, Date March 17, 2011."},{"key":"10.1016\/j.lpm.2011.11.013_bib0720","unstructured":"Source: \u201cTable 9.12a: Adjusted Patient Survival, Deceased Donor Liver Transplants Survival at 3 Months, 1 Year, 5 Years, and 10 Years\u201d, The Scientific Registry of Transplant Recipients (SRTR), under contract with the U.S. Department of Health and Human Services, 2009 Report."},{"key":"10.1016\/j.lpm.2011.11.013_bib0725","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/01.tp.0000241104.58576.e6","article-title":"Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: analysis of UNOS Database","volume":"82","author":"Simpson","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.lpm.2011.11.013_bib0730","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/01.TP.0000071204.03720.BB","article-title":"Analysis of the United Network for Organ Sharing database comparing renal allografts and patient survival in combined liver-kidney transplantation with the contralateral allografts in kidney alone or kidney-pancreas transplantation","volume":"76","author":"Fong","year":"2003","journal-title":"Transplantation"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211006403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498211006403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T04:11:15Z","timestamp":1686715875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498211006403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":146,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0755498211006403"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2011.11.013","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}